about
Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells.Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotypeMITF in melanoma: mechanisms behind its expression and activity.MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment.Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.Anti-apoptotic proteins on guard of melanoma cell survival.Pro-survival role of MITF in melanoma.Phenotypic diversity of patient-derived melanoma populations in stem cell medium.[BH3 mimetics as a strategy to complement anticancer therapies]Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemiaWhole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cellsTYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAFV600E melanoma cellsInhibitors of HSP90 in melanomaBCL-w: apoptotic and non-apoptotic role in health and diseasePlasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation ProgramDissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticityPhysiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypesNon-Apoptotic Cell Death Signaling Pathways in Melanoma17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines
P50
Q35111429-32E5949D-FD36-4F50-9D38-8A03B424C82FQ35147858-7DEE228C-5E68-46DE-8565-04C1F8F06050Q35187734-878A4A7A-E2F1-45CC-957F-9CC3D6245B00Q35650051-9C4F2CB4-99C5-45BE-B525-40157B57A75EQ37977487-86BFBA5F-4AA4-410E-8C19-F2204C929D4FQ38075980-369B8303-C8A1-4C16-87E3-31E94821239AQ38241749-63FE11BB-5A41-440F-95AF-895C038D7652Q51641309-BEEC9AC8-0236-44BA-99F2-4313AA96EB80Q60521041-91765D3B-E782-4743-9289-0DF741A906D9Q86497132-B3BD56BA-2E46-4134-8E52-B67567C76F0AQ90579327-40DE428F-FE55-47E0-B0BE-894096DA9FD5Q90785402-6CCA4FBA-C364-41F7-B7D7-EC65641718C5Q90977099-4D404E75-B4E2-4C3D-81E6-B584F04F5BE4Q92130235-48EE727D-C109-45E1-9F62-5C47C79C8892Q92240577-F6F0CDC7-8E88-455C-B1DB-3CFCA5F6384EQ92632442-0583566B-3098-4D37-8126-303170EA6C3BQ92960597-B3B7BF81-AACB-447E-8485-8277C091D5CDQ93118409-D543BEA3-C2F7-4422-92A7-CCF2A3292B63Q93263334-04DF1D93-105A-4812-9AB3-B084E8A93199Q95930988-676F1EA6-8541-41D7-BDF5-672D4A371BD1
P50
description
researcher ORCID ID = 0000-0002-2231-3740
@en
wetenschapper
@nl
name
Mariusz L Hartman
@ast
Mariusz L Hartman
@en
Mariusz L Hartman
@es
Mariusz L Hartman
@nl
type
label
Mariusz L Hartman
@ast
Mariusz L Hartman
@en
Mariusz L Hartman
@es
Mariusz L Hartman
@nl
prefLabel
Mariusz L Hartman
@ast
Mariusz L Hartman
@en
Mariusz L Hartman
@es
Mariusz L Hartman
@nl
P106
P1153
55769000900
P31
P496
0000-0002-2231-3740